english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic

 COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view.
1 September 2021

Viral vector covid-19 vaccine ChAdOx1-S (Vaxzevria°) and covid-19. Efficacy in the short term, but a risk of rare, sometimes fatal, thrombosis

FEATURED REVIEW Following two mRNA vaccines, a viral vector vaccine, the covid-19 vaccine ChAdOx1-S (Vaxzevria°, AstraZeneca), has been authorised in the European Union. Like the two mRNA vaccines, this vaccine triggers an immune response against the S glycoprotein of Sars-CoV-2.
Full review (3 pages) available for download by subscribers.
1 September 2021

In the September issue of Prescrire International - Psoriasis and ixekizumab: turn first to standard systemic treatments

FREE DOWNLOAD There is no strong evidence that ixekizumab has greater efficacy than methotrexate in patients with psoriasis. In addition, its adverse effects are less well established than those of standard treatments, particularly in the long term.
Full text available for free download.
1 September 2021

Preventable deaths

 Editorial  A number of high-profile court cases have brought attention to thousands of victims made sick by their medication. It is within our grasp to prevent many patients from becoming victims, without waiting for scandals to erupt, by being cautious and attentive: attentive, first and foremost, to doing no harm.
1 September 2021

Drug-induced sudden cardiac death and long QT syndrome

Many drugs directly increase the QT interval on the electrocardiogram, a disorder of electrical conduction associated with a risk of sometimes fatal cardiac disorders.
1 September 2021

Stopping antidepressant therapy: plan tapered withdrawal

When stopping antidepressant therapy, reducing the dose stepwise over a period of more than 4 weeks helps to limit withdrawal symptoms.
1 September 2021

Prescrire's annual review: drug packaging in 2020

Drug packaging is a key determinant of drug quality and is sometimes the deciding factor when choosing between treatments, in the interests of safety. It is still too often neglected by drug companies and regulators.
1 September 2021

Trabectedin (Yondelis°): more dangerous than beneficial in ovarian cancer, yet the EMA maintains its position

 Outlook  The European Medicines Agency chose not to take into account data showing the significant toxicity of trabectedin and the lack of a tangible clinical benefit for patients. It is up to healthcare professionals to avoid exposing patients to this drug, which is more dangerous than beneficial.
1 September 2021

Low-dose methotrexate: 2-year follow-up of adverse events

FEATURED REVIEW Low-dose methotrexate is a useful first-line treatment in a range of autoimmune diseases such as rheumatoid arthritis. A 2-year follow-up of several thousand patients provides new estimates of the frequency of adverse events.
Full review (2 pages) available for download by subscribers.
1 July 2021

In the July-August issue of Prescrire International: fusidic acid + betamethasone valerate cream (Dermafusone°) and infected atopic eczema

FREE DOWNLOAD Atopic eczema is sometimes complicated by infection, most often caused by Staphylococcus aureus ("golden staph"), with the development of pustules and crusting. How do Prescrire's editors rate fusidic acid + betamethasone valerate cream in this situation?
Full text available for free download.
1 July 2021

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90